Remove DNA Remove Immune Response Remove In-Vivo Remove Scientist
article thumbnail

Q&A with Mark Garner: The golden age of cancer research  

Drug Discovery World

MG: I am responsible for Agilent’s cancer segment. A fulfilling part of my job is meeting the scientists, companies, and institutions at the forefront of ground-breaking research that are advancing patient health outcomes. Mark Garner, PhD., RA: Please can you tell us a bit more about your role at Agilent?

article thumbnail

What to expect from PEGS Europe 2023: Day 3

Drug Discovery World

Enkelejda Miho, PhD, Professor, University of Applied Sciences and Arts Northwestern Switzerland, and Managing Director, aiNET, on: ‘The singular immune response to dengue and machine learning identification of antibodies in high-throughput sequences’.

Protein 57